ClinicalTrials.gg
TerminatedNCT01337609Updated Aug 9, 2013Results posted

Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder

A Phase 4 interventional study of Ganeden BC30 and Placebo (sugar pill) in Major Depressive Disorder and Irritable Bowel Syndrome, sponsored by Massachusetts General Hospital. Terminated at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-08-09.

Sponsored by Massachusetts General Hospital · Phase 4, Interventional, and Treatment

How we know

Why this study was terminated
Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Depressive Disorder, Major by Massachusetts General Hospital — 9 open to participants now, 12 under way, none of them phase 3. Depressive Disorder, Major · Massachusetts General Hospital.

Enrollment
71st of 77
5 · median 40
Started
2011
with 4 others
Phase 4
15 of 88
1 open now
Registered
31st of 88
by date

Among the 88 studies in Depressive Disorder, Major by Massachusetts General Hospital, this one is the 71st largest by enrollment of the 77 interventional ones that give a count, is one of 5 that started in 2011, is one of 15 in phase 4, and was the 31st registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

9 of the 88 studies in Depressive Disorder, Major by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Depressive Disorder, Major by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and effectiveness of a nutritional supplement, the probiotic bacteria GanedenBC30. Probiotics are live microorganisms which when taken in large enough amounts are supposed to provide a health benefit. The investigators would like to see whether this supplement can be used as a treatment for Irritable Bowel Syndrome (IBS) and Major Depressive Disorder (MDD). Participants in the study will have both IBS and MDD. In order to find out if GanedenBC30 is effective in treating IBS and MDD, the investigators will compare it to a placebo. About 32 people will take part in this research study. About half of these 32 people will take part at Charles River Medical Associates and half will take part at Burlington Medical Associates. Participants will be recruited from among patients already being seen at Charles River Medical Associates or Burlington Medical Associates for their primary care. The study will last for two months, during which time participants will make eight study visits and will take either Ganeden BC30 or placebo. The investigators hypothesize that subjects treated with the probiotic will have significantly better outcomes with regard to depression and IBS symptoms compared to those who receive placebo.

03

Conditions studied

  • Major Depressive Disorder
  • Irritable Bowel Syndrome

Keywords

  • Depression
  • Irritable Bowel Syndrome
  • Probiotic
  • Bacillus Coagulans
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to give
  • Meet criteria for Irritable Bowel Syndrome
  • Meet criteria for Major Depressive Disorder
  • Men and women ages 18 to 65
  • Women of must be using an adequate methods of
  • Can be on an antidepressant medications, but must have been on the medication for at least 8 weeks and at a stable dose for 4 weeks
  • Can be on medications for IBS, but must have been on medications for at least 8 weeks and at a stable dose for 4 weeks

Exclusion criteria

Exclusion Criteria:

  • Patients who have failed one or more trials of probiotics for IBS
  • Patients who report an inadequate response to less than two or more than four adequate trails of antidepressant treatments during the current depressive episode at a therapeutic dose for an adequate duration
  • Women who are pregnant or breastfeeding
  • Patients with "alarm signs" or "red flags" as defined by American Gastroenterological Association (AGA) are excluded [6], unless they have been fully evaluated to rule out other significant diseases.
  • Patients with known diagnoses of digestive organic disease, celiac disease and lactose intolerance prior to the screening.
  • Patients who report an inadequate response (less than 50% decrease in depressive symptom severity) to less than two or more than four prior adequate trials of antidepressant treatments during the current depressive episode (including monotherapy treatment and distinct combination regimens) at a therapeutic dose (as defined by the MGH-ATRQ) and for an adequate duration (minimum six weeks for any monotherapy).
  • Patients who report treatment with adjunctive medications to their antidepressant for a minimum of four weeks during the current depressive episode.
  • Patients with a current need for involuntary commitment or who have been hospitalized within four weeks of the Screening Visit for the current major depressive episode.
  • Patients who have received ECT during the current episode.
  • Patients who have a current Axis I diagnosis of:

Delirium, dementia, amnestic, or other cognitive disorder; Schizophrenia or other psychotic disorder, based on the PDSQ; Bipolar I or II disorder, based on the PDSQ; Patients with a Axis II () diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder.

  • Patients experiencing hallucinations, delusions, or any psychotic symptomatology in the current depressive episode.
  • Patients who have met DSM-IV-TR criteria for any significant substance use disorder within the past six months, based on the PDSQ.
  • Patients receiving new onset depression-focused psychotherapy within 6 weeks of screening, or at any time during participation in the trial.
  • Patients who have been previously randomized in a probiotics clinical trial (lifetime).
  • Patients who have participated in any clinical trial with an drug or device within the past month.
  • Patients who, in the opinion of the investigator, are actively suicidal or homicidal and at significant risk for suicide or homicide.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    GanedenBC30

    Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.

    Drug: Ganeden BC30

  • Placebo comparator
    Sugar pill

    Arm 2 will take placebo (sugar pill) for 60 days.

    Other: Placebo (sugar pill)

  • Other
    Ganeden BC30, Sugar pill

    Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.

    Other: Ganeden BC30, Placebo (sugar pill)

Interventions

  • DrugHeyndrickxia coagulansStudies of Heyndrickxia coagulansHeyndrickxia coagulans pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2 billion CFU per capsule; One pill daily for 60 days

  • OtherPlacebo (sugar pill)

    1 pill daily for 60 days

  • OtherGaneden BC30, Placebo (sugar pill)

    Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days

06

What researchers measure

Primary outcomes

  1. Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)

    The Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)is a self report measure that addresses depressive symptoms. MDD responders will be defined as those exhibiting a 50% decrease in the QIDS SR at study endpoint.

    Time frame: Administered at each of 8 study visits (every 10 days), Endpoint is Final Visit

Secondary outcomes

  1. IBS Severity Scoring System (IBS-SSS)

    The IBS-SSS is a validated instrument used to assess common IBS symptoms over the past 10 days including abdominal pain, distention, bowel habit, and global function. The IBS-SSS will be used to assess the absolute change in specific IBS symptoms at endpoint, namely the bloating/distension score.

    Time frame: Adminsitered at each of 8 study visits (every 10 days), Endpoint is Final Visit

  2. Visual Analog Scale (VAS)

    The VAS is a self-administered measure of abdominal pain, discomfort, and bloating. The change in total score from baseline to study endpoint will be assessed.

    Time frame: Administered at each of 8 study visits (every 10 days), Endpoint is Final Visit

  3. Adequate Relief of IBS Pain (AR-IBS)

    The AR-IBS is a self-administered measure of the adequacy of the relief of IBS pain.

    Time frame: Adminstered at each of 8 visits (every 10 days), Endpoint is Final Visit

  4. Patient Global Impression of Change (PGI-C) - IBS Symptoms

    The PGI-C is a self-administered measure of the degree of improvement in IBS symptoms compared to the first study visit. Degree of improvement in IBS symptoms from first to final visit will be assessed using this scale.

    Time frame: Administered at each of 8 visits (every 10 days), Endpoint is Final Visit

07

Results

Posted Aug 9, 2013
Limitations and caveats
Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and data were not analyzed.

Participant flow

Participant flow — Overall Study
MilestoneGanedenBC30Sugar PillGaneden BC30, Sugar Pill
Started122
Completed022
Not completed100

Outcome measures

PrimaryQuick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)

The Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)is a self report measure that addresses depressive symptoms. MDD responders will be defined as those exhibiting a 50% decrease in the QIDS SR at study endpoint.

Time frame:
Administered at each of 8 study visits (every 10 days), Endpoint is Final Visit

No measurements were reported for this outcome.

SecondaryIBS Severity Scoring System (IBS-SSS)

The IBS-SSS is a validated instrument used to assess common IBS symptoms over the past 10 days including abdominal pain, distention, bowel habit, and global function. The IBS-SSS will be used to assess the absolute change in specific IBS symptoms at endpoint, namely the bloating/distension score.

Time frame:
Adminsitered at each of 8 study visits (every 10 days), Endpoint is Final Visit

No measurements were reported for this outcome.

SecondaryVisual Analog Scale (VAS)

The VAS is a self-administered measure of abdominal pain, discomfort, and bloating. The change in total score from baseline to study endpoint will be assessed.

Time frame:
Administered at each of 8 study visits (every 10 days), Endpoint is Final Visit

No measurements were reported for this outcome.

SecondaryAdequate Relief of IBS Pain (AR-IBS)

The AR-IBS is a self-administered measure of the adequacy of the relief of IBS pain.

Time frame:
Adminstered at each of 8 visits (every 10 days), Endpoint is Final Visit

No measurements were reported for this outcome.

SecondaryPatient Global Impression of Change (PGI-C) - IBS Symptoms

The PGI-C is a self-administered measure of the degree of improvement in IBS symptoms compared to the first study visit. Degree of improvement in IBS symptoms from first to final visit will be assessed using this scale.

Time frame:
Administered at each of 8 visits (every 10 days), Endpoint is Final Visit

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo for 60 Days—0/2 (0%)0/2 (0%)
GanedenBC30 for 60 Days—0/1 (0%)1/1 (100%)
Placebo for 30 Days, Followed by GanedenBC30 for 30 Days—0/2 (0%)1/2 (50%)
Most frequent other events
Most frequent other events
EventPlacebo for 60 DaysGanedenBC30 for 60 DaysPlacebo for 30 Days, Followed by GanedenBC30 for 30 Days
Cerebral infarct; residual leg weakness and face droopingCardiac disorders0/21/10/2
Labial cyst, constipation, and tension headacheGastrointestinal disorders0/20/11/2
Sore throatImmune system disorders0/20/11/2
Sinus infectionInfections and infestations0/20/11/2
Right flank painMusculoskeletal and connective tissue disorders0/20/11/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)GanedenBC30Sugar PillGaneden BC30, Sugar PillTotal
<=18 years0000
Between 18 and 65 years1225
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)GanedenBC30Sugar PillGaneden BC30, Sugar PillTotal
Female1225
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GanedenBC30Sugar PillGaneden BC30, Sugar PillTotal
Hispanic or Latino0000
Not Hispanic or Latino1225
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GanedenBC30Sugar PillGaneden BC30, Sugar PillTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White1225
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)GanedenBC30Sugar PillGaneden BC30, Sugar PillTotal
United States1225
08

Study locations

2 sites
  • Burlington Medical Associates
    Burlington, Massachusetts 01803, United States
  • Charles River Medical Associates
    Westborough, Massachusetts 01581, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2011
First posted
Apr 19, 2011
Start
Jun 2011
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results first posted
Aug 9, 2013
Last update
Aug 9, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01337609
Collaborators
Ganeden Biotech, Inc.
Responsible party
Maurizio Fava, MD (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Apr 19, 2011
Start date
Jun 2011
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Aug 9, 2013
Last update
Aug 9, 2013

Study contacts

Maurizio Fava, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Heyndrickxia coagulans

Start the discussion